These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 27021495)

  • 61. [Severe Yellow fever vaccine-associated disease: a case report and current overview].
    Slesak G; Gabriel M; Domingo C; Schäfer J
    Dtsch Med Wochenschr; 2017 Aug; 142(16):1219-1222. PubMed ID: 28810279
    [No Abstract]   [Full Text] [Related]  

  • 62. Enhanced safety surveillance of STAMARIL® yellow fever vaccine provided under the expanded access investigational new drug program in the USA.
    Rojas A; Hachey W; Kaur G; Korejwo J; Muhammad R
    J Travel Med; 2023 Nov; 30(7):. PubMed ID: 37000007
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Immune response during adverse events after 17D-derived yellow fever vaccination in Europe.
    Bae HG; Domingo C; Tenorio A; de Ory F; Muñoz J; Weber P; Teuwen DE; Niedrig M
    J Infect Dis; 2008 Jun; 197(11):1577-84. PubMed ID: 18419548
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Vaccination coverage survey versus administrative data in the assessment of mass yellow fever immunization in internally displaced persons--Liberia, 2004.
    Huhn GD; Brown J; Perea W; Berthe A; Otero H; LiBeau G; Maksha N; Sankoh M; Montgomery S; Marfin A; Admassu M
    Vaccine; 2006 Feb; 24(6):730-7. PubMed ID: 16182416
    [TBL] [Abstract][Full Text] [Related]  

  • 65. First case of yellow fever vaccine-associated viscerotropic disease (YEL-AVD) in Hong Kong.
    Leung WS; Chan MC; Chik SH; Tsang TY
    J Travel Med; 2016 Apr; 23(4):. PubMed ID: 27087559
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Yellow fever vaccination and increased relapse rate in travelers with multiple sclerosis.
    Farez MF; Correale J
    Arch Neurol; 2011 Oct; 68(10):1267-71. PubMed ID: 21670384
    [TBL] [Abstract][Full Text] [Related]  

  • 67. No booster dose for yellow fever vaccination: what are the consequences for the activity of vaccination in travel clinics?
    Wyplosz B; Leroy JP; Derradji O; Consigny PH
    J Travel Med; 2015; 22(2):140-1. PubMed ID: 25384441
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A case suspected for yellow fever vaccine-associated viscerotropic disease in the Netherlands.
    van de Pol EM; Gisolf EH; Richter C
    J Travel Med; 2014; 21(6):421-4. PubMed ID: 24920138
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Planned Yellow Fever Primary Vaccination Is Safe and Immunogenic in Patients With Autoimmune Diseases: A Prospective Non-interventional Study.
    Valim V; Machado KLLL; Miyamoto ST; Pinto AD; Rocha PCM; Serrano EV; Dinis VG; Gouvêa SA; Dias JGF; Campi-Azevedo AC; Teixeira-Carvalho A; Peruhype-Magalhães V; da Costa-Rocha IA; de Lima SMB; Miranda EH; Trindade GF; Maia MLS; Gavi MBRO; da Silva LB; Duque RH; Gianordoli APE; Casagrande TZ; Oliveira KG; Moura BCDM; Nicole-Batista F; Rodrigues LC; Clemente TB; Magalhães ES; Bissoli MF; Gouvea MDPG; Pinto-Neto LFDS; Costa CZ; Giovelli RA; Brandão LR; Polito ETL; Koehlert IO; Borjaille BP; Pereira DB; Dias LH; Merlo DL; Genelhu LFF; Pretti FZ; Giacomin MDS; Burian APN; Fantinato FFST; Pileggi GS; da Mota LMH; Martins-Filho OA
    Front Immunol; 2020; 11():1382. PubMed ID: 32765496
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Seroconversion and antibody persistence after yellow fever vaccination in people living with HIV: impact of baseline HIV viral load and yellow fever seropositivity.
    Martin C; Florence E; Domingo C; Delforge M; De Wit S; Dauby N
    J Travel Med; 2022 Dec; 29(8):. PubMed ID: 35285913
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Yellow fever - prevention in travellers.
    Neilson AA; Mayer CA
    Aust Fam Physician; 2010 Aug; 39(8):570-3. PubMed ID: 20877751
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Duration of post-vaccination immunity against yellow fever in adults.
    Collaborative group for studies on yellow fever vaccines
    Vaccine; 2014 Sep; 32(39):4977-84. PubMed ID: 25090646
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever.
    Jentes ES; Poumerol G; Gershman MD; Hill DR; Lemarchand J; Lewis RF; Staples JE; Tomori O; Wilder-Smith A; Monath TP;
    Lancet Infect Dis; 2011 Aug; 11(8):622-32. PubMed ID: 21798462
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Is the absence or intermittent YF vaccination the major contributor to its persistent outbreaks in eastern Africa?
    Baba MM; Ikusemoran M
    Biochem Biophys Res Commun; 2017 Oct; 492(4):548-557. PubMed ID: 28109882
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Reactogenicity of yellow fever vaccines in a randomized, placebo-controlled trial.
    Camacho LA; de Aguiar SG; Freire Mda S; Leal Mda L; do Nascimento JP; Iguchi T; Lozana JA; Farias RH;
    Rev Saude Publica; 2005 Jun; 39(3):413-20. PubMed ID: 15997317
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Yellow fever: epidemiology and prevention.
    Barnett ED
    Clin Infect Dis; 2007 Mar; 44(6):850-6. PubMed ID: 17304460
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Travellers' profile, travel patterns and vaccine practices--a 10-year prospective study in a Swiss Travel Clinic.
    Boubaker R; Meige P; Mialet C; Buffat CN; Uwanyiligira M; Widmer F; Rochat J; Fossati AH; Souvannaraj-Blanchant M; Payot S; Rochat L; de Vallière S; Genton B; D'Acremont V
    J Travel Med; 2016 Jan; 23(1):. PubMed ID: 26792229
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Vaccine administration decision making: the case of yellow fever vaccine.
    Lown BA; Chen LH; Wilson ME; Sisson E; Gershman M; Yanni E; Jentes ES; Hochberg NS; Hamer DH; Barnett ED
    Clin Infect Dis; 2012 Sep; 55(6):837-43. PubMed ID: 22670048
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Safety profile of fractional dosing of the 17DD Yellow Fever Vaccine among males and females: Experience of a community-based pharmacovigilance in Kinshasa, DR Congo.
    Nzolo D; Engo Biongo A; Kuemmerle A; Lusakibanza M; Lula Y; Nsengi N; Nsibu Ndosimao C; Tona Lutete G; Van Geertruyden JP
    Vaccine; 2018 Oct; 36(41):6170-6182. PubMed ID: 30190119
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Early molecular correlates of adverse events following yellow fever vaccination.
    Chan CY; Chan KR; Chua CJ; Nur Hazirah S; Ghosh S; Ooi EE; Low JG
    JCI Insight; 2017 Oct; 2(19):. PubMed ID: 28978802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.